Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
David Y. Graham & Maria Pina Dore. (2016) Helicobacter pylori therapy: a paradigm shift. Expert Review of Anti-infective Therapy 14:6, pages 577-585.
Read now
Read now
Francis Mégraud. (2013) Current recommendations for therapies in a world of evolving resistance. Gut Microbes 4:6, pages 541-548.
Read now
Read now
W. Baffone, F. Belbusti, E. Barbieri, A. Pianetti, F. Bruscolini, M.T. Fabi, L. Salvaggio & A. Albano. (1997) Comparison of Colloidal Bismuth Subcitrate and Metronidazole, Both in Combination with an H2-Antagonist as Therapy for Helicobacter pylori
. Journal of Chemotherapy 9:3, pages 208-212.
Read now
Read now
P. Unge & A. Berstad. (1996) Pooled Analysis of Anti-Helicobacter pylori Treatment Regimens. Scandinavian Journal of Gastroenterology 31:sup220, pages 27-40.
Read now
Read now
P. Unge. (1996) Review of Helicobacter pylori Eradication Regimens. Scandinavian Journal of Gastroenterology 31:sup215, pages 74-81.
Read now
Read now
J. R. Lambert, S. K. Lin & J. Aranda-Michel. (1995) Helicobacter pylori. Scandinavian Journal of Gastroenterology 30:sup208, pages 33-46.
Read now
Read now
J. S. Dixon. (1995) Helicobacter pylori Eradication: Unravelling the Facts. Scandinavian Journal of Gastroenterology 30:sup212, pages 48-62.
Read now
Read now
Leslie A. Noach, Wies L. Langenberg, Mauro A. Bertola, Jaap Dankert & Guido N. J. Tytgat. (1994) Impact of Metronidazole Resistance on the Eradication of Helicobacter pylori. Scandinavian Journal of Infectious Diseases 26:3, pages 321-327.
Read now
Read now
Articles from other publishers (24)
Yu Huang, Jinnan Chen, Zhaohui Ding, Xi Chen, Xiao Liang, Xin Zeng, Fei Xu, Yuehua Han & Hong Lu. (2023) Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial. Journal of Gastroenterology 58:7, pages 633-641.
Crossref
Crossref
Marouf Alhalabi, Mohammed Waleed Alassi, Kamal Alaa Eddin & Khaled Cheha. (2021) Efficacy of two-week therapy with doxycycline-based quadruple regimen versus levofloxacin concomitant regimen for helicobacter pylori infection: a prospective single-center randomized controlled trial. BMC Infectious Diseases 21:1.
Crossref
Crossref
Jixiang Zhao, Yunzhi Zou, Ke Li, Xin Huang, Changping Niu, Zikang Wang, Shuyang Zhao, Yizhen Zhang, Conghua Song & Yong Xie. (2021)
Doxycycline and minocycline in
Helicobacter pylori
treatment: A systematic review and meta‐analysis
. Helicobacter 26:5.
Crossref
Crossref
Olga P. NyssenAngeles Perez-AisaBojan TepesManuel Castro-FernandezJuozas KupcinskasLaimas JonaitisLuis BujandaAlfredo LucendoNatasa Brglez JurecicJorge Perez-LasalaOleg ShvetsGalina FadeenkoJose M. HuguetZdenki KikecDmitry BordinIrina VoynovanMarcis LejaJose Carlos MachadoMiguel AreiaLuis Fernandez-SalazarLuis RodrigoSergey AlekseenkoJesus BarrioJuan OrtuñoMonica PeronaLiudmila VologzhaninaPilar Mata RomeroOleg ZaytsevTheodore RokkasSotirios GeorgopoulosRinaldo PellicanoGyorgy M. BuzasInes ModolellBlas Jose Gomez RodriguezIlkay SimsekCem SimsekMarina Roldan LafuenteTatiana IlchishinaJudith Gomez CamareroManuel Dominguez-CajalVassiliki NtouliNatalia Nikolaevna DekhnichPerminder PhullOscar NuñezFrode LerangMarino VeneritoFrederic HeluwaertAnte TonkicMaria CaldasIgnasi PuigFrancis MegraudColm O'MorainJavier P. Gisbert. (2021) Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg). American Journal of Gastroenterology 116:6, pages 1220-1229.
Crossref
Crossref
Olga P. Nyssen, Angeles Perez‐Aisa, Luis Rodrigo, Manuel Castro, Pilar Mata Romero, Juan Ortuño, Jesus Barrio, Jose Maria Huguet, Ines Modollel, Noelia Alcaide, Alfredo Lucendo, Xavier Calvet, Monica Perona, Barbara Gomez, Blas Jose Gomez Rodriguez, Pilar Varela, Manuel Jimenez‐Moreno, Manuel Dominguez‐Cajal, Liliana Pozzati, Diego Burgos‐Santamaria, Luis Bujanda, Jenifer Hinojosa, Javier Molina‐Infante, Tommaso Di Maira, Luis Ferrer, Luis Fernández‐Salazar, Ariadna Figuerola, Llucia Tito, Cristobal Coba, Judith Gomez‐Camarero, Nuria Fernandez, Maria Caldas, Ana Garre, Elena Resina, Ignasi Puig, Colm O’Morain, Francis Megraud & Javier P. Gisbert. (2020)
Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for
Helicobacter pylori
infection: Spanish data of the European
Helicobacter pylori
Registry (Hp‐EuReg)
. Helicobacter 25:5.
Crossref
Crossref
Doron Boltin, Zohar Levi, Rachel Gingold-Belfer, Hagit Gabay, Tzippy Shochat, Hemda Schmilovitz-Weiss, Iris Dotan & Shlomo Birkenfeld. (2020) Effect of Previous Nitroimidazole Treatment on Helicobacter pylori Eradication Success. Journal of Clinical Gastroenterology 54:4, pages 333-337.
Crossref
Crossref
Diego Burgos‐Santamaría, Adrian G. McNicholl & Javier P. Gisbert. (2019)
Empirical
Helicobacter pylori
rescue therapy: an 18‐year single‐centre study of 1200 patients
. GastroHep 1:6, pages 311-324.
Crossref
Crossref
David Y. Graham & Sun-Young Lee. (2015) How to Effectively Use Bismuth Quadruple Therapy. Gastroenterology Clinics of North America 44:3, pages 537-563.
Crossref
Crossref
Nuno Almeida, José M. Romãozinho, Maria M. Donato, Cristina Luxo, Olga Cardoso, Maria A. Cipriano, Carol Marinho & Carlos Sofia. (2014)
Triple Therapy with High-Dose Proton-Pump Inhibitor, Amoxicillin, and Doxycycline Is Useless for
Helicobacter pylori
Eradication: A Proof-of-Concept Study
. Helicobacter 19:2, pages 90-97.
Crossref
Crossref
Tomasz Z Jodlowski, Sum Lam & Charles Ft AshbyJrJr. (2008) Emerging Therapies for the Treatment of Helicobacter pylori Infections. Annals of Pharmacotherapy 42:11, pages 1621-1639.
Crossref
Crossref
G. Cammarota, A. Martino, G. Pirozzi, R. Cianci, G. Branca, E. C. Nista, A. Cazzato, O. Cannizzaro, L. Miele, A. Grieco, A. Gasbarrini & G. Gasbarrini. (2004) High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 19:7, pages 789-795.
Crossref
Crossref
X. Calvet & E. Gené. (2003) Erradicar Helicobacter pylori.¿Terapia triple o cuádruple?, ¿corta o larga?. Gastroenterología y Hepatología 26:5, pages 325-329.
Crossref
Crossref
Peter Malfertheiner, Andreas Leodolter & Ulrich Peitz. (2000) Cure of Helicobacter pylori -associated ulcer disease through eradication. Best Practice & Research Clinical Gastroenterology 14:1, pages 119-132.
Crossref
Crossref
Shauna M. Buring, Lawrence H. Winner, Randy C. Hatton & Paul L. Doering. (2012)
Discontinuation Rates of
Helicobacter pylori
Treatment Regimens: A Meta‐Analysis
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 19:3, pages 324-332.
Crossref
Crossref
Thor-Henrik Henriksen, Gunnar Nysæter, Tesfaye Madebo, Degefe Setegn, Øystein Brorson, Tedla Kebede & Arnold Berstad. (1999) Peptic ulcer disease in south Ethiopia is strongly associated with Helicobacter pylori. Transactions of the Royal Society of Tropical Medicine and Hygiene 93:2, pages 171-173.
Crossref
Crossref
P. Unge. 1999. Gastroduodenal Disease and Helicobacter pylori. Gastroduodenal Disease and Helicobacter pylori
261
300
.
Peter Unge. (1997) What Other Regimens Are Under Investigation to Treat Helicobacter pylori Infection?. Gastroenterology 113:6, pages S131-S148.
Crossref
Crossref
Stephan Miehlke & David Y. Graham. (1997) Antimicrobial therapy of peptic ulcers. International Journal of Antimicrobial Agents 8:3, pages 171-178.
Crossref
Crossref
S E PerkinsL L YanZ ShenA HaywardJ C MurphyJ G Fox. (1996) Use of PCR and culture to detect Helicobacter pylori in naturally infected cats following triple antimicrobial therapy. Antimicrobial Agents and Chemotherapy 40:6, pages 1486-1490.
Crossref
Crossref
TSENG‐SHING CHEN, SHYH‐HAW TSAY, FULL‐YOUNG CHANG & SHOU‐DONG LEE. (2008)
Triple therapy for the eradication of
Helicobacter pylori
and reduction of duodenal ulcer relapse: Comparison of 1 week and 2 week regimens and recrudescence rates over 12 months
. Journal of Gastroenterology and Hepatology 10:3, pages 300-305.
Crossref
Crossref
J. G. PENSTON. (2007) Review article: Helicobacter pylori eradication–understandable caution but no excuse for inertia. Alimentary Pharmacology & Therapeutics 8:4, pages 369-389.
Crossref
Crossref
G. N. J. TYTGAT. (2007) Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Alimentary Pharmacology & Therapeutics 8:4, pages 359-368.
Crossref
Crossref
M. H. E. REIJERS, L. A. NOACH & G. N. J. TYTGAT. (2007) Short report: evaluation of Helicobacter pylori eradication with bismuth sucrlfate. Alimentary Pharmacology & Therapeutics 8:3, pages 351-352.
Crossref
Crossref
G. N. J. Tytgat & L. A. Noach. 1994. Helicobacter pylori. Helicobacter pylori
550
569
.